According to @stocktalkweekly, JPMorgan initiated coverage on CRISPR Therapeutics (CRSP) at Overweight with a Dec-2026 price target of $70 (source: @stocktalkweekly). The source reports JPMorgan sees CRSP nearing several portfolio inflection points, with partnered Casgevy and approximately $2 billion in cash providing valuation support (source: @stocktalkweekly). The source notes JPMorgan views CRSP’s setup and outlook as differentiated versus other gene-editing peers, with Casgevy’s commercial levers well understood (source: @stocktalkweekly). The source adds JPMorgan expects Casgevy sales to ramp and net profits to accrue to CRSP near term, and that a milder preconditioning regimen could help CRSP gain additional credit for its stake in the franchise (source: @stocktalkweekly). The source makes no mention of any cryptocurrency market impact (source: @stocktalkweekly).